Top 5 Drug Type | Count |
---|---|
Small molecule drug | 6 |
Monoclonal antibody | 3 |
AAV based gene therapy | 1 |
Diagnostic radiopharmaceuticals | 1 |
Antibody | 1 |
Target |
Mechanism CD44 modulators [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism Viral proteins inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism ACVR2B inhibitors [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Oct 2025 |
Sponsor / Collaborator |
Start Date22 Jul 2024 |
Sponsor / Collaborator |
Start Date01 Jul 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Hyaluronic acid/Fluorouracil ( CD44 x TYMS ) | Colorectal Cancer More | Phase 2 |
ISLA-101 ( Viral proteins ) | Dengue More | Preclinical |
8C7 mAb (Monash University) ( ADAM10 ) | Colorectal Cancer More | Preclinical |
rAAV-based gene therapy (Baker IDI Heart & Diabetes Institute/Monash University/University of Melbourne) ( ACVR2B ) | Cachexia More | Preclinical |
Chikungunya Vaccine(Technovalia) | Chikungunya Fever More | Preclinical |